Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-25
Trial Details
NCT Number NCT07335198
Lead Sponsor GlaxoSmithKline
Conditions Non-alcoholic Fatty Liver Disease
Enrollment 30 participants
Start Date 2026-03-05
Primary Completion 2026-09-04 (estimated)
Study Completion 2026-09-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-24